UK markets open in 3 hours 40 minutes

Xeris Pharmaceuticals, Inc. (XERS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.8300-0.0400 (-2.14%)
At close: 4:00PM EDT
1.8300 0.00 (0.00%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.8700
Open1.8500
Bid1.8300 x 3100
Ask1.8900 x 4000
Day's range1.8000 - 1.8650
52-week range1.7700 - 7.9400
Volume1,113,894
Avg. volume3,505,035
Market cap229.352M
Beta (5Y monthly)1.81
PE ratio (TTM)N/A
EPS (TTM)-1.4730
Earnings date08 Nov 2021 - 12 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.00
  • Business Wire

    Xeris Pharmaceuticals Enters Collaboration Agreement With Merck

    CHICAGO, October 25, 2021--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an option to license Xeris’ suspension-based formulation technology, XeriJect™, for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulation

  • Business Wire

    Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

    CHICAGO, October 05, 2021--Xeris Pharmaceuticals, Inc. ("Xeris"), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) ("Strongbridge"). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdin

  • Business Wire

    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    CHICAGO, October 01, 2021--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on October 1, 2021, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 28,750 shares of its common stock to 20 new employee(s) under Xeris’ Inducement Equity Plan.